NEW YORK--(BUSINESS WIRE)--Medidata, a Dassault Systèmes company, was rated the pharmaceutical industry’s preferred provider of electronic data capture (EDC) solutions in a new report by Industry Standard Research. This report also identified Medidata’s Rave EDC as the No. 1 most recently used EDC system across the industry.
“We understand that for our customers and their patients, a robust, secure, and flexible EDC system is the cornerstone of a successful clinical trial,” says Wayne Walker, senior vice president, Rave Platform Technology, Medidata. “This recognition reinforces our belief that we have the groundbreaking technological solutions and expertise needed to meet our clients’ evolving needs.”
The EDC Benchmarking and Market Dynamics (5th Ed.) report surveyed 114 respondents on a range of topics, including EDC provider performance, EDC selection criteria, and EDC trends. Respondents from North America, Europe, and Asia selected Rave EDC as the most preferred solution based on the ease of use for sites, sponsors, and contract research organizations (CROs), scalability, real-time data access, capability for mid-study changes, and technical support and training.
Leveraging tools like EDC help set the pace and determine the success of an entire study. Customers are looking for clinical trial technology solutions that are flexible and scalable and provide data confidence as a study progresses. Ultimately, robust EDC benefits patients by accelerating promising drug development and bringing new medicines to market more quickly and efficiently.
Medidata is a pioneer of EDC and a leader in the industry. The Medidata Platform, the company’s unified life sciences platform, which includes Rave EDC, connects patients, sites, sponsors, and partners in a secure and scalable cloud environment to bring life changing treatments to those who need them most.
Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.
Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. With over 20 years of groundbreaking technological innovation across more than 30,000 trials and 9 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across 2,100+ customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes company (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.
About Dassault Systèmes
Dassault Systèmes, the 3DEXPERIENCE® Company, is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all – consumers, patients and citizens. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.com
© Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries.